RXO Relative Valuation
RXO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RXO is overvalued; if below, it's undervalued.
Historical Valuation
RXO Inc (RXO) is now in the Undervalued zone, suggesting that its current forward PE ratio of 19.26 is considered Undervalued compared with the five-year average of . The fair price of RXO Inc (RXO) is between 25.45 to 47.56 according to relative valuation methord. Compared to the current price of 13.48 USD , RXO Inc is Undervalued By 47.04%.
Relative Value
Fair Zone
25.45-47.56
Current Price：13.48
47.04%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.36
P/B
Median3y
3.73
Median5y
3.73
-2.47
FCF Yield
Median3y
3.40
Median5y
3.40
Competitors Valuation Multiple
The average P/S ratio for RXO's competitors is 4.98, providing a benchmark for relative valuation. RXO Inc Corp (RXO) exhibits a P/S ratio of 0.53, which is -89.42% above the industry average. Given its robust revenue growth of 70.45%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is RXO Inc (RXO) currently overvalued or undervalued?
What is RXO Inc (RXO) fair value?
How does RXO's valuation metrics compare to the industry average?
What is the current P/B ratio for RXO Inc (RXO) as of Apr 28 2025?
What is the current FCF Yield for RXO Inc (RXO) as of Apr 28 2025?
What is the current Forward P/E ratio for RXO Inc (RXO) as of Apr 28 2025?